What are the best evidence-based alternatives to Restasis for moderate dry eye that do not cause initial stinging upon application?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What are the best evidence-based alternatives to Restasis for moderate dry eye that do not cause initial stinging upon application?
3 real searches · 1 real-search pass
dry eye disease treatment alternatives lifitegrast cyclosporine perfluorohexyloctane varenicline nasal spray clinical trials burning stinging FDA labelGoogle ↗
OBSERVED
FDA prescribing information Miebo Xiidra Cequa Tyrvaya dry eye instillation site pain burning stingingGoogle ↗
OBSERVED
American Academy Ophthalmology dry eye treatment guideline lifitegrast cyclosporine MGD perfluorohexyloctaneGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
dry eye disease treatment alternatives lifitegrast cyclosporine perfluorohexyloctane varenicline nasal spray clinical trials burning stinging FDA label Google ↗
FDA prescribing information Miebo Xiidra Cequa Tyrvaya dry eye instillation site pain burning stinging Google ↗
American Academy Ophthalmology dry eye treatment guideline lifitegrast cyclosporine MGD perfluorohexyloctane Google ↗
- These highlights do not include all the information needed to use TRYPTYR® safely and effectively. See full prescribing information for TRYPTYR . TRYPTYR (acoltremon ophthalmic solution) 0.003%, for topical ophthalmic use Initial U.S. Approval: 2025 · dailymed.nlm.nih.gov
- Drug Trials Snapshot: TRYPTYR · fda.gov
- AAO Dry Eye Syndrome Guideline Summary 2024 Preferred Practice Pattern · guidelinecentral.com
- Dry Eye Syndrome Preferred Practice Pattern® · aaojournal.org
- These highlights do not include all the information needed to use MIEBO safely and effectively. See full prescribing information for MIEBO. MIEBO ®(perfluorohexyloctane ophthalmic solution), for topical ophthalmic use Initial U.S. Approval: 2023 · dailymed.nlm.nih.gov
- label · accessdata.fda.gov
- These highlights do not include all the information needed to use CEQUA safely and effectively. See full prescribing information for CEQUA. CEQUA® (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic useInitial U.S. Approval: 1983 · dailymed.nlm.nih.gov
- Improved Dry Eye Drugs for 2025 and Beyond · aao.org
- These highlights do not include all the information needed to use VEVYE ®safely and effectively. See full prescribing information for VEVYE. VEVYE (cyclosporine ophthalmic solution) 0.1%, for topical ophthalmic use Initial U.S. Approval: 1983 · dailymed.nlm.nih.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
dry eye disease treatment alternatives lifitegrast cyclosporine perfluorohexyloctane varenicline nasal spray clinical trials burning stinging FDA label OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA prescribing information Miebo Xiidra Cequa Tyrvaya dry eye instillation site pain burning stinging OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
American Academy Ophthalmology dry eye treatment guideline lifitegrast cyclosporine MGD perfluorohexyloctane OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |